|
| |
| | | 68314 | | 09.02.2023 | | Roche Pharma (Schweiz) AG | | | | | | | 09.02.2027 | | | | | | 07.16.10. | | | | 07.16.10. | | IP |
| | Seq.-No. | Product | Description | Galenic form | ATC-classification | |
|---|
| 01 | Lunsumio 1 mg/1 ml | Konzentrat zur Herstellung einer Infusionslösung | Concentrate for infusion (Mosunetuzumabum 1 mg/ml) | L01FX25 | | | 02 | Lunsumio 30 mg/30 ml | Konzentrat zur Herstellung einer Infusionslösung | Concentrate for infusion (Mosunetuzumabum 30mg / 30ml) | L01FX25 | | | 03 | Lunsumio | | (Mosunetuzumabum 1 mg) | | | | 04 | Lunsumio | | (Mosunetuzumabum 30 mg) | | |
|
|
|
